Trial Profile

A Phase 1b study of HTL0048149

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HTL 0048149 (Primary)
Indications Schizophrenia
Focus Adverse reactions
Sponsors Nxera Pharma

Most Recent Events

01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
13 Mar 2024 New trial record
11 Mar 2024 According to Sosei Heptares media release, Sosei Heptares will retain control and act as sponsor of this trial until option exercise, estimated in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com